Melanoma genomics - will we go beyond BRAF in clinics?

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Next-generation sequencing has advanced cancer genomics, yet clinical application for melanoma lags.
• Current clinical practice primarily relies on BRAF V600 mutation testing for advanced melanoma treatment.
• There's an urgent need for novel therapeutic targets and biomarkers to enable personalized melanoma therapy.

Purpose of the Study:

• To provide an updated overview of the molecular landscape of melanoma.
• To compare genomic profiles of melanoma, focusing on common driver genes.
• To propose a comprehensive gene panel for enhanced melanoma diagnostics and treatment.

Main Methods:

• Review of existing literature on melanoma molecular subtypes and genomic alterations.
• Analysis and comparison of genomic profiles from recent melanoma studies.
• Identification and selection of key melanoma-associated genes for a diagnostic panel.

Main Results:

• Established melanoma subtypes include BRAF+, NRAS+, NF1+, and triple WT.
• Emerging genes like PREX2, ERBB4, PPP6C, FBXW7, PIK3CA, and IDH1 are implicated in melanoma.
• Genomic profile comparisons highlight the evolution of understanding melanoma genetics.

Conclusions:

• Current clinical genomic testing for melanoma remains limited despite extensive research.
• A proposed 22-gene panel offers a more comprehensive approach for melanoma-specific and pan-cancer genomic tests.
• Implementing advanced genomic insights can significantly improve personalized melanoma treatment strategies.